Significance of T2 lesions in multiple sclerosis: A 13-year longitudinal study

Annals of Neurology

Volumn 60, Issue 2, 2006, Pages 236-242

  Rudick, Richard A ^a   Lee, Jar Chi ^a   Simon, Jack ^b   Fisher, Elizabeth ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BRAIN TISSUE; CLINICAL ARTICLE; CORRELATION ANALYSIS; DISEASE SEVERITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOMES RESEARCH; PRIORITY JOURNAL; RELAPSE; REMISSION; SCORING SYSTEM;

ADULT; BRAIN; DISABILITY EVALUATION; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NEUROPSYCHOLOGICAL TESTS; PREDICTIVE VALUE OF TESTS; REGRESSION ANALYSIS; SPINAL CORD; TREATMENT OUTCOME;

EID: 33746790166     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20883     Document Type: Article

References (27)

1. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998;121:495-503.
2. Filippi M, Horsfield MA, Morrissey SP, et al. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 1994;44: 635-641.
3. Sailer M, O'Riordan JI, Thompson AJ, et al. Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination. Neurology 1999;52:599-606.
4. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol 1996;39:6-16.
5. Rudick RA, Lee JC, Simon J, et al. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004; 56:548-555.
6. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995;45: 255-260.
7. The IFN-b Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:656-661.
8. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999; 46:197-206.
9. Mammi S, Filippi M, Martinelli V, et al. Correlation between brain MRI lesion volume and disability in patients with multiple sclerosis. Acta Neurol Scand 1996;94:93-96.
10. Miki Y, Grossman RI, Udupa JK, et al. Relapsing-remitting multiple sclerosis: longitudinal analysis of MR images-lack of correlation between changes in T2 lesion volume and clinical findings. Radiology 1999;213:395-399.
11. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. Curr Opin Neurol 2002;15:239-245.
12. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) [published erratum appears in Ann Neurol 1996 Sep;40(3):480]. Ann Neurol 1996;39:285-294.
13. Rudick RA, Cutter G, Baier M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001;56:1324-1330.
14. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002; 59:1412-1420.
15. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33: 1444-1452.
16. Rudick R, Antel J, Confavreux C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997;42:379-382.
17. Rudick RA, Fisher E, Lee JC, et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53:1698-1704.
18. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular Interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79-87.
19. Jacobs L, Cookfair DL, Rudick RA, et al. A phase III trial of intramuscular recombinant beta interferon as treatment for exacerbating- remitting multiple sclerosis: design and conduct of study and baseline characteristics of patients. Mult Scler 1995; 1:118-135.
20. Hiehle JF, Grossman RI, Ramer KN, et al. Magnetization transfer effects in MR-detected multiple sclerosis lesions: comparison with gadolinium-enhanced spin-echo images and non-enhanced T1-weighted images. AJNR Am J Neuroradiol 1995; 16:69-77.
21. Zivadinov R, Zorzon M. Is gadolinium enhancement predictive of the development of brain atrophy in multiple sclerosis? A review of the literature. J Neuroimaging 2002;12:302-309.
22. Paolillo A, Piattella MC, Pantano P, et al. The relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis: a monthly MRI study after triple-dose gadolinium-DTPA. J Neurol 2004;251: 432-439.
23. Trojano M, Liguori M, Bosco ZG, et al. Age-related disability in multiple sclerosis. Ann Neurol 2002;51:475-480.
24. Ezekiel F, Chao L, Kornak J, et al. Comparisons between global and focal brain atrophy rates in normal aging and Alzheimer disease: Boundary Shift Integral versus tracing of the entorhinal cortex and hippocampus. Alzheimer Dis Assoc Disord 2004;18: 196-201.
25. Enzinger C, Fazekas F, Matthews PM, et al. Risk factors for progression of brain atrophy in aging: six-year follow-up of normal subjects. Neurology 2005;64:1704-1711.
26. Runmarker B, Andersen O, Anderson O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 1993;116:117-134.
27. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 1989;112:1419-1428.